Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 5 for:    Fabrazyme | Recruiting, Active, not recruiting, Enrolling by invitation Studies | Fabry disease

A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04281537
Recruitment Status : Active, not recruiting
First Posted : February 24, 2020
Last Update Posted : October 8, 2020
Sponsor:
Information provided by (Responsible Party):
Amicus Therapeutics

Brief Summary:
This is an international, non-interventional research study of adult patients with Fabry Disease and their caregivers. The study will comprise a prospective time and motion evaluation and a cross-sectional evaluation of patient and caregiver-reported outcomes. The study will evaluate the time associated with the preparation and administration of a single dose of ERT in patients by health care providers as well as the impact on Fabry patients and caregivers time and costs associated with an ERT treatment. The study will also evaluate the patients' quality of life wellbeing, fatigue and work productivity.

Condition or disease Intervention/treatment
Fabry Disease Drug: Agalsidase Beta Drug: Agalsidase Alpha

Layout table for study information
Study Type : Observational
Estimated Enrollment : 120 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: A Multi-country Time and Motion Study to Describe the Experience of Clinicians, Patients and Their Caregivers During the Treatment of Fabry Disease With Enzyme Replacement Therapy With Agalsidase Alfa and Agalsidase Beta
Actual Study Start Date : March 1, 2020
Estimated Primary Completion Date : May 1, 2021
Estimated Study Completion Date : May 1, 2021


Group/Cohort Intervention/treatment
Patient with Fabry Disease on ERT (agalsidase alfa)
Patients with Fabry Disease receiving Enzyme Replacement Therapy (agalsidase alfa)
Drug: Agalsidase Alpha
Enzyme Replacement Therapy - Infusion every other week

Patient with Fabry Disease on ERT (agalsidase beta)
Patients with Fabry Disease receiving Enzyme Replacement Therapy (agalsidase beta)
Drug: Agalsidase Beta
Enzyme Replacement Therapy - Infusion every other week

Caregiver
Caregiver of patient with Fabry Disease on ERT



Primary Outcome Measures :
  1. Total time spent by HCPs in the preparation and administration of a single dose of ERT in patients with FD; stratified by country and by ERT product (agalsidase alfa or agalsidase beta). [ Time Frame: up to 7 weeks ]

Secondary Outcome Measures :
  1. Total time spent by HCPs on each separate task associated with the preparation and administration of a single dose of ERT (with agalsidase alfa or agalsidase beta). [ Time Frame: up to 7 weeks ]
  2. Total patient time associated with attendance for the administration of a single dose of ERT (with agalsidase alfa or agalsidase beta). [ Time Frame: up to 7 weeks ]
  3. Total costs associated with attendance for the administration of a single dose of ERT (with agalsidase alfa or agalsidase beta). [ Time Frame: up to 7 weeks ]
  4. Proportion of patients with work absence due to attendance for this ERT episode. [ Time Frame: up to 7 weeks ]
  5. Number of hours of patient work absence due to attendance for this ERT episode. [ Time Frame: up to 7 weeks ]
  6. Total caregiver time associated with accompanying a patient with FD for the administration of a single dose of ERT (with agalsidase alfa or agalsidase beta). [ Time Frame: up to 7 weeks ]
  7. Total costs associated with accompanying a patient with FD for the administration of a single dose of ERT (with agalsidase alfa or agalsidase beta). [ Time Frame: up to 7 weeks ]
  8. Proportion of caregivers with work absence due to accompanying the patient for this ERT episode. [ Time Frame: up to 7 weeks ]
  9. Number of hours of caregivers work absence due to accompanying the patient for this ERT episode. [ Time Frame: up to 7 weeks ]
  10. HRQoL (SF-12 scores / responses) [ Time Frame: up to 7 weeks ]

    Health Related Quality of Life measured by the 12 Item Short Form Survey [SF-12]). SF-12v2 component summary measure and health domain scale is described in terms of scale or item composition, number of score levels, lowest and highest possible T scores for the standard and acute forms, and the health states associated with the lowest and highest observable scores. These descriptions are based on the general content of the scales and measures and the pattern of responses necessary to achieve these extreme scores. This information can be used to summarize what each component summary measure and health domain scale measures and can serve as a basis for broad-level interpretation of SF-12v2 results.

    These 8 domains form 2 subscales: physical component summary and mental component summary. The low scores indicate limitations in the domain measured. The high scores indicate less limitations in the domain measured.


  11. Patients General wellbeing measured by WHO-5 scores / responses) [ Time Frame: up to 7 weeks ]
    World Health Organization-5 Wellbeing Index [WHO-5] consists of 5 items and the timeframe for responses is based on the previous 2 weeks. The 5 items relate to feeling cheerful, calm, active, rested and being interested in life. The raw score is calculated by totaling the figures of the five answers. The raw score ranges from 0 to 25, 0 representing worst possible and 25 representing best possible quality of life.

  12. Patients Level of fatigue measured by Fatigue Likert scale) [ Time Frame: up to 7 weeks ]
    Questionnaire measuring Fatigue. The range is from 1-5. 1 not at all tired, 5 extremely tired

  13. Patients Levels of work impairment (WPAI scores / responses) [ Time Frame: up to 7 weeks ]
    Work Productivity and Activity Index. The WPAI consists of 6 items and ranges from 0-100%. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.

  14. Caregiver's Levels of work impairment (WPAI-CG scores / responses). [ Time Frame: up to 7 weeks ]
    Work Productivity and Activity Index. The WPAI consists of 6 items and ranges from 0-100%. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.

  15. Level of strain in providing care for a patient with FD (CSI scores / responses). [ Time Frame: up to 7 weeks ]
    Caregiver Strain index. The CSI consists of 13 items and measures the strain of care provision in five domains (financial, physical, psychological, social and personal). The range is from 0-13 and any positive answer may indicate a need for intervention in that area. A score of 7 or higher indicates a high level of stress.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Patients with FD who are receiving ERT and their caregivers will be identified and recruited from approximately 12 specialist centres in four countries (Taiwan, Turkey, Brazil and Japan).
Criteria

Patient Inclusion Criteria:

  • Patients with a documented diagnosis of FD
  • Patients who have received ≥4 doses of ERT (with agalsidase alfa or agalsidase beta) for the treatment of FD.
  • Patients who present to the participating hospital(s) or treatment centre(s) for administration of a dose of ERT (as part of their routine treatment) during the data collection period.

Caregiver Inclusion Criteria:

-Self-identifies as a caregiver of a patient with FD for whom written informed consent has been obtained for inclusion in the study.

Patient Exclusion Criteria:

  • Patients who are unable or unwilling to give consent for study participation.
  • Patients whose ERT preparation and administration takes place exclusively in the home setting with no HCP involvement in preparation of the infusion.
  • For the time and motion evaluation: Patients whose ERT is administered by a HCP who does not consent to be observed.

Caregiver Exclusion Criteria:

- Caregiver (and/or the patient with FD whom they support or care for) is unable or unwilling to give consent for study participation.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04281537


Locations
Layout table for location information
United States, New Jersey
Amicus Therapeutics, Inc.
Cranbury, New Jersey, United States, 08512
Sponsors and Collaborators
Amicus Therapeutics
Layout table for additonal information
Responsible Party: Amicus Therapeutics
ClinicalTrials.gov Identifier: NCT04281537    
Other Study ID Numbers: AT-NIS-0001
First Posted: February 24, 2020    Key Record Dates
Last Update Posted: October 8, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Fabry Disease
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Cerebral Small Vessel Diseases
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders
Sphingolipidoses
Metabolism, Inborn Errors
Lipidoses
Lipid Metabolism, Inborn Errors